Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects

Clinical Pharmacology and Therapeutics

Volumn 59, Issue 6, 1996, Pages 636-646

  Nieforth, Keith A ^a   Nadeau, Rosemary ^a   Patel, Indravadan H ^a   Mould, Diane ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOPLASM PROTEIN; MACROGOL; MYXOVIRUS RESISTANCE PROTEIN; RECOMBINANT ALPHA2A INTERFERON; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG CONJUGATION; DRUG HALF LIFE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; MALE; MODEL; NORMAL HUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG EVALUATION; GTP-BINDING PROTEINS; HALF-LIFE; HUMANS; INTERFERON ALFA-2A; MALE; MODELS, CHEMICAL; POLYETHYLENE GLYCOLS; PROTEIN BIOSYNTHESIS; TIME FACTORS;

EID: 0029683637     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90003-X     Document Type: Article

References (27)

1. Issacs A, Lindenmann J. Virus interference; I: the interferon. Proc R Soc Lond B Biol Sci 1957;147:258-67.
2. Samuel CE. Antiviral actions of interferon - interferon-regulated cellular proteins and their surprisingly selective antiviral activities. Virology 1991;183:1-11.
3. Müller U, Steinhoff U, Reis LF, et al. Functional role of type I and type II interferons in antiviral defense. Science 1994;264:1918-21.
4. Dorr RT. Interferon-α in malignant and viral diseases: a review. Drugs 1993;45:177-211.
5. Witt PL, Storer BE, Bryan GT, et al. Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-β. J Immunother 1993; 13:191-200.
6. Abei M, Fäh J, Hurt N, et al. cDNA structures and regulation of two interferon-induced human MX proteins. Mol Cell Biol 1989;9:5062-72.
7. Pavlovic J, Staeheli P. The antiviral potentials of MX proteins. J Interferon Res 1991;11:215-9.
8. Pavlovic J, Zürcher T, Haller O, Staeheli P. Resistance to influenza virus and vesicular stomatitis virus conferred by expression of human MxA protein. J Virol 1990;64:3370-5.
9. Staeheli P, Pitossi F, Pavlovic J. MX proteins: GTPases with antiviral activity. Trends Cell Biol 1993;3:268-72.
10. Speiser DE, Zürcher T, Ramseier H, et al. Nuclear myxovirus-resistance protein MX is a minor histocompatibility antigen. Proc Natl Acad Sci USA 1990;87: 2021-5.
11. Schiller JH, Storer B, Witt PL, et al. Biological and clinical effects of the combination of β- and γ-interferons administered as a 5-day continuous infusion. Cancer Res 1990;50:4588-94.
12. Liberati AM, Horisberger MA, Palmisano L, et al. Double-blind randomized phase I study of the clinical tolerance and biological effects of natural and recombinant interferon. J Interferon Res 1992;12:329-36.
13. Hoofnagle JH, Mullen KD, Jones DB. Treatment of chronic non-A non-B hepatitis with recombinant human alpha interferon: a preliminary report. N Engl J Med 1986;315:1575-8.
14. Abuchowski A, van Es T, Palczuk NC, Davis FF. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 1977;252:3578-81.
15. Abuchowski A, McCoy JR, Palczuk NC, van Es T, Davis FF. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 1977;252:3582-6.
16. Fuertges F, Abuchowski A. The clinical efficacy of poly(ethylene glycol)-modified proteins. J Control Rel 1990;11:139-48.
17. Nucci ML, Shorr R, Abuchowski A. The therapeutic value of poly(ethylene glycol)-modified proteins. Adv Drug Delivery Rev 1991;6:133-51.
18. Wills RJ, Dennis S, Spiegel HE, Gibson DM, Nadler PI. Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection. Clin Pharmacol Ther 1984;35:722-7.
19. Barouki FM, Witter FR, Griffin D, et al. Time course of interferon levels, antiviral state, 2′,5′-oligoadenylate synthetase and side effects in healthy men. J Interferon Res 1987;7:29-39.
20. Gallati H. Interferon: a greatly simplified immuno enzyme determination with two monoclonal antibodies [German]. J Clin Chem Clin Biochem 1982;20: 907-14.
21. Oh S, Luhowskyj S, Witt P, et al. Quantitation of interferon-induced Mx protein in whole blood lysates by an immunochemiluminescent assay: elimination of protease activity of cell lysates in toto. J Immunol Methods 1994;176:79-91.
22. Roferon-A product information. In: The physician's desk reference. 49th ed. Montvale, NJ: Medical Economics, 1995:2055-8.
23. Zhi J, Teller SB, Satoh H, Koss-Twardy SG, Luke DR. Influence of human serum albumin content in formulations on the bioequivalency of interferon alfa-2a given by subcutaneous injection in healthy male volunteers. J Clin Pharmacol 1995;35:281-4.
24. Jusko WJ, Ko HC. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 1994;56:406-19.
25. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993;21:457-78.
26. Chua CC, Greenberg ML, Viau AT, Nucci M, Brenckman WD, Hershfield MS. Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma. Ann Intern Med 1988;109:114-7.
27. Jakschies D, Hochkeppel H, Horisberger M, Deicher H, von Wussow P. Emergence and decay of the human Mx Homolog in cancer patients during and after interferon-α therapy. J Biol Resp Mod 1990;9:305-12.